Daiichi Sankyo, Merck deal

Daiichi’s Plexxikon Inc. subsidiary and Merck partnered to evaluate Plexxikon’s PLX3397 and Merck’s melanoma drug Keytruda pembrolizumab in a Phase I/II trial in patients with advanced melanoma and solid tumors. The companies expect to begin enrollment by mid-year. ...